京新药业(002020.SZ)：上半年净利润3.88亿元 同比下降3.54%

Core Viewpoint - Jingxin Pharmaceutical (002020.SZ) reported a decline in revenue and net profit for the first half of the year, indicating challenges in the pharmaceutical sector while showing growth in medical device revenue [1] Financial Performance - The company achieved a total revenue of 2.017 billion yuan, a year-on-year decrease of 6.20% [1] - Finished drug revenue was 1.175 billion yuan, down 9.68% year-on-year [1] - Raw material drug revenue reached 453 million yuan, a decline of 9.59% year-on-year [1] - Medical device revenue increased to 349 million yuan, reflecting a growth of 12.01% year-on-year [1] - The net profit attributable to the parent company was 388 million yuan, a decrease of 3.54% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 360 million yuan, showing a year-on-year increase of 7.78% [1]